Next Article in Journal
31st Annual GP2A Medicinal Chemistry Conference
Next Article in Special Issue
Sebetralstat: A Rapidly Acting Oral Plasma Kallikrein Inhibitor for the On-Demand Treatment of Hereditary Angioedema
Previous Article in Journal
Plant-Derived Natural Products: A Source for Drug Discovery and Development
Previous Article in Special Issue
Bradykinin-Mediated Angioedema Induced by Commonly Used Cardiovascular Drugs
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
DDC
Volume 3
Issue 1
10.3390/ddc3010012
ddc-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Drugs Drug Candidates 2023, 2(3), 538-553.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. Drugs Drug Candidates 2023, 2, 538–553

by
François Marceau
Axe Microbiologie-Infectiologie et Immunologie, Research Center, CHU de Québec-Université Laval, Québec, QC G1V 4G2, Canada
Drugs Drug Candidates 2024, 3(1), 208; https://doi.org/10.3390/ddc3010012
Submission received: 23 January 2024 / Accepted: 29 January 2024 / Published: 22 February 2024
(This article belongs to the Special Issue Drugs of the Kallikrein-Kinin System)
Versions Notes
In the original publication [1], there were mistake in Tables 3 and 4 as published.
Error in Table 3
In the original publication, there was a mistake in Table 3 as published. In the line starting with “Diabetic macula edema”, the highlighted and italicized number should have been 9, not 8.
Error in Table 4
In the original publication, there was a mistake in Table 4 as published. In the line dealing with breast cancer, “NPA” should have been replaced with “agonist”.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. Drugs Drug Candidates 2023, 2, 538–553. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Marceau, F. Correction: Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. Drugs Drug Candidates 2023, 2, 538–553. Drugs Drug Candidates 2024, 3, 208. https://doi.org/10.3390/ddc3010012

AMA Style

Marceau F. Correction: Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. Drugs Drug Candidates 2023, 2, 538–553. Drugs and Drug Candidates. 2024; 3(1):208. https://doi.org/10.3390/ddc3010012

Chicago/Turabian Style

Marceau, François. 2024. "Correction: Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. Drugs Drug Candidates 2023, 2, 538–553" Drugs and Drug Candidates 3, no. 1: 208. https://doi.org/10.3390/ddc3010012

APA Style

Marceau, F. (2024). Correction: Marceau, F. Drugs of the Kallikrein–Kinin System: An Overview. Drugs Drug Candidates 2023, 2, 538–553. Drugs and Drug Candidates, 3(1), 208. https://doi.org/10.3390/ddc3010012

Article Metrics

Back to TopTop